Is Pembrolizumab a targeted drug or an immune drug?

Pembrolizumab (Pembrolizumab) is an immunotherapy drug and an immune checkpoint inhibitor. It restores the immune system's ability to attack cancer cells by inhibiting the binding of the immune checkpoint molecule PD-1 to its ligand PD-L1. As a result, pembrolizumab can boost a patient's immune response and help the body fight the growth and spread of tumors.

Pembrolizumab, as an immune checkpoint inhibitor, enhances the body's immune system's ability to attack cancer cells by inhibiting the interaction betweenPD-1 (programmed death-1) receptor and its ligand PD-L1 (programmed death ligand-1). It is not a traditional targeted drug and does not directly target specific mutations or abnormal signaling pathways of tumor cells. Instead, it inhibits tumor growth and spread by regulating immune responses. Although pembrolizumab is an immune drug, it is often used in clinical practice in combination with other treatments such as chemotherapy and radiotherapy to obtain better therapeutic effects.

PembrolizumabThe original drug is already on the market in China. SpecificationsThe price per box of 100mg/4ml may be around RMB 15,000. This drug is a strictly controlled drug and has not yet been included in medical insurance. Pembrolizumab The price of the European version of the original drug 100mg/4ml per box may be around RMB 25,000, and the price of the Turkish version of 100mg/4ml per box may be around 10,000 RMB (the price may fluctuate due to the exchange rate). The ingredients of the original drugs at home and abroad are basically the same, and they are expensive. There are currently no generic versions of Pembrolizumab available overseas.